Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

Semaglutide

Drug and asset intelligence for Semaglutide with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 1
Stage: Development stage unavailable

Sponsor company

Novo Nordisk →

Mechanism of action

GLP-1 Agonists

Recent signals(3)

ClinicalAugust 4, 2026

Semaglutide (Wegovy) Under Investigation for Trichotillomania Treatment

A clinical trial is underway to evaluate the safety and effectiveness of semaglutide for treating trichotillomania.

RegulatoryJune 22, 2026

Semaglutide tablet approved in the UK for weight loss

The semaglutide tablet has received approval from the MHRA for weight loss and management in the UK.

June 17, 2026

FDA Proposes Exclusion of Semaglutide, Tirzepatide, and Liraglutide from 503B Bulks List

The FDA has proposed to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, indicating no clinical need for compounding these drugs.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(1)

Topline Data

Novo Nordisk — Semaglutide

June 17, 2026 · N/A

Indications

Behavioral Disorders →

Therapeutic areas

Behavioral Disorders →

Endocrinology →

Endocrinology · GLP-1 Agonists →

GLP-1 Agonists →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.